Blocking the activity of an essential protein to treat T-cell acute lymphoblastic leukaemia
Dr Maarten Hoogenkamp will continue his work into blocking the EAAT1 protein, which is crucial for the growth of T-cell acute lymphoblastic leukaemia.
Creating innovative new treatments for childhood rhabdomyosarcoma by harnessing the body’s natural defence system
Dr Matthew Blunt aims to create and test immunotherapy treatments for rhabdomyosarcoma that are safer and more effective than chemotherapy.
Developing a new drug for the treatment of ALT-positive cancers
Dr Jon Elkins and Dr Anna Rose at the University of Oxford hope to develop a new drug which will affect vital ALT-positive cancer cell processes.
Finding kinder drugs in genetically matched cell models for childhood leukaemia
Professor Alex Thompson and his team at the University of Nottingham aim to learn more about leukaemia to support the development of kinder treatments.
Creating advanced models to test new treatments for malignant rhabdoid tumours
Dr Daniel Williamson’s expert team will find the best malignant rhabdoid tumour models to test exciting new treatments.
Degrading the anaplastic lymphoma kinase protein to treat paediatric cancers
Dr Lizzie Tucker will assess a new type of treatment to fight ALK-driven childhood cancers like neuroblastoma.
Making CAR-T cells that can rest to improve their cancer-fighting ability
Professor John Anderson’s team at University College London Great Ormond Street Institute of Child Health aim to revolutionise CAR T-cell therapy for solid tumours.
Finding the best way to make two cancer-targeting T cells for the price of one
Professor John Anderson at University College London hopes to develop a cost-effective CAR T-cell combination therapy.
Fighting brain cancer with CAR-T cells: Targeting zombie cells to improve therapy
Dr Ashley Vardon at the University of Birmingham hopes to find a way to effectively fight diffuse midline glioma with new immunotherapies.